Hepatite C

Perlin, Cássio Marques; Groto, Anderson Dillmann; Perlin, Gustavo Olivo; Salamanca, Mayara Angélica Bolson

doi:10.11606/issn.1679-9836.v98i5p341-348

Cited by 2 publications

(1 citation statement)

References 52 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A busca por tratamentos que apresentem maior efetividade e segurança e com menores efeitos adversos tem sido os maiores obstáculos que os pesquisadores enfrentam (15). Dessa forma, o objetivo do presente trabalho foi realizar uma revisão bibliográfica atualizada sobre os fármacos preconizados no Brasil para o tratamento da hepatite C, demonstrando os mecanismos de ação e possíveis reações adversas.…”

Section: Ns5bunclassified

Mecanismo De Ação E Reações Adversas Dos Antivirais Preconizados Para Hepatite C No Brasil

Júnior¹,

Silva

Souza

2021

Infarma

View full text Add to dashboard Cite

A hepatite C é uma doença que afeta toda população mundial, afetando também a qualidade de vida da população. O uso de medicamentos é fundamental para o processo terapêutico dos pacientes com hepatite C. O tratamento da hepatite C enfrentou diversos obstáculos com a diversidade pangenotípica viral e as reações adversas do tratamento enfrentadas pelos infectados com o vírus. Entretanto, com o decorrer dos anos, a evolução do mercado farmacêutico e dos medicamentos antivirais ocorreu em diversos campos da pesquisa contra a hepatite C. Neste contexto se torna importante compreender os mecanismos de ação e reações adversas dos fármacos utilizados para o tratamento da hepatite C no Brasil. A pesquisa trata de uma revisão bibliográfica, por meio de levantamento de artigos científicos nas bases de dados LILACs, Pubmed, Google Acadêmico e SciELO, portarias e boletins do Ministério da Saúde. Melhorias moleculares dos fármacos visam diminuir o tempo de tratamento, aumentando assim a adesão do paciente, pelo fato desses novos medicamentos apresentarem efeitos adversos mais leves. A tendência da indústria farmacêutica, no que diz respeito ao tratamento da hepatite C, é produzir medicamentos pangenotípicos, ou seja, que atuam em todos os genótipos do VHC.

show abstract

Section: Ns5bunclassified

Mecanismo De Ação E Reações Adversas Dos Antivirais Preconizados Para Hepatite C No Brasil

Júnior¹,

Silva

Souza

2021

Infarma

View full text Add to dashboard Cite

show abstract

Development of approaches to the evaluation of pharmacotherapy effectiveness for chronic hepatitis C

Narkevich,

Tsitlionok

2023

Farmakoèkonomika

View full text Add to dashboard Cite

Objective: to analyse the consumption pattern of antiviral therapy (AVT) for chronic hepatitis C on the example of an infectious hospital.Material and methods. The study was based on data from 380 discharge summaries of an infectious diseases hospital for 2011–2019. The criterion of sampling was the established diagnosis of chronic hepatitis C. The first line therapy regimens were analyzed and compared; the calculations were based on direct treatment costs of the study sample. The pharmacoeconomic effectiveness of therapy was assessed by calculating the cost-effectiveness ratio (CER).Results. A retrospective analysis of patients’ sampling allowed to establish a general profile: a 40-year-old man with hepatitis C virus genotype 1 and a mild degree of liver fibrosis. A total of 18 international nonproprietary names (17 trade names) were used for AVT. The pattern of drugs prescribed correlated with the clinical guidelines for the studied period and allowed to distinguish the beginning of the transition from interferon-based regimens to direct-acting antivirals (DAAs). The change in the treatment paradigm was associated not only with increased efficacy in achieving a sustained virological response, but also with minimization of side effects. The high frequency of prescribing interferon regimens as AVT was accompanied by low rates of achieving virus elimination (63.69%), high frequency of relapses (12.88%), as well as the lack of response to pharmacological correction (21.32%) and premature discontinuation of therapy due to adverse events (2.11%). A total of 142,450,414.91 rubles was spent on the first line pharmacotherapy in the study cohort during the study period. Costs per 1 patient with the diagnosis “chronic hepatitis C” and F0–F3 fibroses according to METAVIR were 372,847.07 rubles with achieving sustained virologic response without relapse in 66% of cases, costs per patient with F4 liver lesion were 398,464.73 rubles (45,16%, respectively).Conclusion. The findings allow us to note the transition from interferon-, nucleoside- and nucleotide-based drugs to DAAs, which can be associated with an increase in therapy effectiveness and proportion of cases with sustained virologic response achieved along with a decrease in the number of adverse events. The results of the study have practical implications for building a strategy for hepatitis C virus elimination in terms of choosing effective pharmacotherapy while reducing the economic burden.

show abstract

Hepatite C

Cited by 2 publications

References 52 publications

Mecanismo De Ação E Reações Adversas Dos Antivirais Preconizados Para Hepatite C No Brasil

Mecanismo De Ação E Reações Adversas Dos Antivirais Preconizados Para Hepatite C No Brasil

Development of approaches to the evaluation of pharmacotherapy effectiveness for chronic hepatitis C

Contact Info

Product

Resources

About